These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29511780)

  • 21. First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.
    Wang L; Lu J; Zhou S; Zhao Y; Xie L; Zhou C; Chen J; Ding S; Xie D; Ding J; Yu Q; Shen H; Hao G; Shao F
    Clin Drug Investig; 2021 Nov; 41(11):999-1010. PubMed ID: 34655432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.
    He YL; Ito H; Yamaguchi M; Terao S; Shimada S; Irie S; Sekiguchi K
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):237-47. PubMed ID: 22456294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
    Gu N; Park MK; Kim TE; Bahng MY; Lim KS; Cho SH; Yoon SH; Cho JY; Jang IJ; Yu KS
    Drug Des Devel Ther; 2014; 8():1709-21. PubMed ID: 25336915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY.
    Guida C; McCulloch LJ; Godazgar M; Stephen SD; Baker C; Basco D; Dong J; Chen D; Clark A; Ramracheya RD
    Diabetes Obes Metab; 2018 Mar; 20(3):571-581. PubMed ID: 28892258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
    Abouelkheir M; El-Metwally TH
    Eur J Pharmacol; 2019 Nov; 862():172638. PubMed ID: 31491403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
    Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
    Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hindbrain DPP-IV inhibition improves glycemic control and promotes negative energy balance.
    Mietlicki-Baase EG; McGrath LE; Koch-Laskowski K; Krawczyk J; Pham T; Lhamo R; Reiner DJ; Hayes MR
    Physiol Behav; 2017 May; 173():9-14. PubMed ID: 28119159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
    Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
    Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
    Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.
    Devin JK; Pretorius M; Nian H; Yu C; Billings FT; Brown NJ
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25158865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men.
    Moon SJ; Yu KS; Kim MG
    Clin Ther; 2020 Jun; 42(6):1047-1057. PubMed ID: 32362346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
    Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
    Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
    Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic modelling of biomarker response to sitagliptin in healthy volunteers.
    Kim BH; Kim SE; Kang D; Lim KS; Kim JR; Jang IJ; Shin SG; Yoon SH; Cho JY; Yu KS
    Basic Clin Pharmacol Toxicol; 2013 Aug; 113(2):113-25. PubMed ID: 23510190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
    Migoya EM; Miller JL; Gutierrez M; Zheng W; Johnson-Levonas AO; Liu Q; Matthews CZ; Wagner JA; Gottesdiener KM
    Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Sitagliptin on Islet Function in Pancreatic Insufficient Cystic Fibrosis With Abnormal Glucose Tolerance.
    Kelly A; Sheikh S; Stefanovski D; Peleckis AJ; Nyirjesy SC; Eiel JN; Sidhaye A; Localio R; Gallop R; De Leon DD; Hadjiliadis D; Rubenstein RC; Rickels MR
    J Clin Endocrinol Metab; 2021 Aug; 106(9):2617-2634. PubMed ID: 34406395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.